EMA will be using temporary premises in the city while construction of the new building takes place, which is not ideal because it requires moving the agency's headquarters twice. / read more /
A collaboration between The Centre for Process Innovation and The Roslin Institute aims to develop commercially viable and scalable methods of producing biologics using transgenic animals. / read more /
The agencies sent warning letters to several companies that the agencies say are illegally marketing unapproved products to treat opioid addiction and withdrawal. / read more /
A manufacturing disruption has led to an EpiPen shortage in Canada, which currently has no alternative auto-injectors available on the market. / read more /
Shire will receive exclusive license to develop and commercialize AB Biosciences' pan receptor interacting molecule program for autoimmune and inflammatory diseases. / read more /
The contract development and manufacturing organization has invested £30-million (US$42 million) at its Dundalk, Ireland site to offer expanded clinical trial services. / read more /
Abuse-deterrent opioid formulations generally fall into two categories: the first is based on a physiochemical abuse-deterrent approach and the second combines the opioid with an antagonist. / read more /
Everyone may not be ready for the deadline, but open standards based on GAMP and GS1 will soon be released; more companies are also leveraging what they’ve learned from serialization to improve overall efficiency. / read more /
Enterprise-wide processes, procedures, and systems are the keys to data integrity and peace of mind, according to Siegfried Schmitt, PhD, principal consultant at PAREXEL. / read more /
pH Adjustment in Pharmaceutical Production
ITW Reagents is fully integrated by AppliChem GmbH and PanReac Química SLU companies, under unique commercial brand PanReac AppliChem. The Division has two production plants in Spain and Germany. / Read more/
Vaccines—from childhood and influenza immunizations, to epidemic prevention, to cancer and therapeutic treatments—present unique development challenges. In this Vaccine and Manufacturing eBook, the editors explore development and manufacturing options to make vaccines more accessible.
